<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03970122</url>
  </required_header>
  <id_info>
    <org_study_id>GFB-887-101</org_study_id>
    <secondary_id>8391348</secondary_id>
    <nct_id>NCT03970122</nct_id>
  </id_info>
  <brief_title>FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects</brief_title>
  <official_title>A First-In-Human, Phase 1, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GFB-887, a TRPC5 Channel Inhibitor, in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Goldfinch Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Goldfinch Bio, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will comprise primarily a single-ascending dose (SAD) escalation component.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double-blind, randomized, placebo-controlled, single-dose, sequential-group design in up to 7
      cohorts of healthy participants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 29, 2019</start_date>
  <completion_date type="Actual">April 4, 2020</completion_date>
  <primary_completion_date type="Actual">March 4, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Dose escalation, parallel assignment</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of AEs</measure>
    <time_frame>Approximately 5.5 weeks</time_frame>
    <description>Safety and tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in laboratory parameters, 12 lead ECG parameters, vital signs measurements, spirometry, and physical examinations</measure>
    <time_frame>Approximately 5.5 weeks</time_frame>
    <description>Safety and tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma PK parameters: Cmax</measure>
    <time_frame>Approximately 5.5 weeks</time_frame>
    <description>PK</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma PK parameters: Tmax</measure>
    <time_frame>Approximately 5.5 weeks</time_frame>
    <description>PK</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma PK parameters: AUC</measure>
    <time_frame>Approximately 5.5 weeks</time_frame>
    <description>PK</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine PK parameters: Ae</measure>
    <time_frame>Approximately 5.5 weeks</time_frame>
    <description>PK</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine PK parameters: Fe</measure>
    <time_frame>Approximately 5.5 weeks</time_frame>
    <description>PK</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine PK parameters: CLR</measure>
    <time_frame>Approximately 5.5 weeks</time_frame>
    <description>PK</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>GFB-887 SAD active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GFB-887 single dose active</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GFB-887 SAD placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>GFB-887 single dose placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GFB-887</intervention_name>
    <description>IMP</description>
    <arm_group_label>GFB-887 SAD active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching</description>
    <arm_group_label>GFB-887 SAD placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Healthy Participant Cohorts - Key Inclusion Criteria:

          1. Males or females, of any race, between 18 and 55 years of age, inclusive, at
             Screening.

          2. Body mass index between 18.0 and 32.0 kg/m^2, inclusive, at Screening.

          3. Systolic blood pressure of between 90 and 140 mmHg, diastolic blood pressure between
             60 and 90 mmHg, and heart rate between 40 and 100 bpm at Screening.

          4. Female participants will be post-menopausal or surgically sterile (as confirmed by
             medical history).

          5. Male participants will agree to use contraception while on study drug and for at least
             90 days after the final follow-up visit.

          6. Able to comprehend and willing to sign an informed consent form (ICF) and to abide by
             the study restrictions.

          7. Participants must be in good health.

        Healthy Participant Cohorts - Key Exclusion Criteria:

          1. Females of childbearing potential.

          2. Significant history or clinically significant manifestation of any metabolic,
             allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,
             gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as
             determined by the Investigator (or designee).

          3. History of alcoholism or drug/chemical abuse within 2 years prior to (first) Check-in.

          4. Use of tobacco or nicotine-containing products within 60 days prior to (first) dosing,
             or positive cotinine at Screening or Check-in.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Males, females of non-childbearing potential</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeanelle Kam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Inc.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2019</study_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glomerulosclerosis</keyword>
  <keyword>proteinuria</keyword>
  <keyword>nephrotic syndrome</keyword>
  <keyword>nephrosis</keyword>
  <keyword>focal segmental glomerulosclerosis</keyword>
  <keyword>kidney diseases</keyword>
  <keyword>urologic diseases</keyword>
  <keyword>glomerulonephritis</keyword>
  <keyword>nephritis</keyword>
  <keyword>diabetic kidney disease</keyword>
  <keyword>diabetic nephropathies</keyword>
  <keyword>endocrine system diseases</keyword>
  <keyword>diabetes complications</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

